188 related articles for article (PubMed ID: 23786490)
1. Crossover versus parallel designs: dose-escalation design comparisons for first-in-human studies.
Yan Z; Hosmane B; Locke C
J Biopharm Stat; 2013; 23(4):804-17. PubMed ID: 23786490
[TBL] [Abstract][Full Text] [Related]
2. Three-dose-cohort designs in cancer phase I trials.
Huang B; Chappell R
Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
[TBL] [Abstract][Full Text] [Related]
3. Design and analysis issues for crossover designs in phase I clinical studies.
Boon PC; Roes KC
J Biopharm Stat; 1999 Mar; 9(1):109-28. PubMed ID: 10091913
[TBL] [Abstract][Full Text] [Related]
4. Optimal crossover designs for logistic regression models in pharmacodynamics.
Waterhouse TH; Eccleston JA; Duffull SB
J Biopharm Stat; 2006; 16(6):881-94. PubMed ID: 17146986
[TBL] [Abstract][Full Text] [Related]
5. How first-time-in-human studies are being performed: a survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004.
Buoen C; Bjerrum OJ; Thomsen MS
J Clin Pharmacol; 2005 Oct; 45(10):1123-36. PubMed ID: 16172177
[TBL] [Abstract][Full Text] [Related]
6. Statistical designs for early phases of cancer clinical trials.
Guan S
J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
[TBL] [Abstract][Full Text] [Related]
7. The impact of baseline covariates on the efficiency of statistical analyses of crossover designs.
Yan Z
Stat Med; 2013 Mar; 32(6):956-63. PubMed ID: 22903413
[TBL] [Abstract][Full Text] [Related]
8. Optimal and efficient crossover designs under different assumptions about the carryover effects.
Hedayat AS; Stufken J
J Biopharm Stat; 2003 Aug; 13(3):519-28. PubMed ID: 12921398
[TBL] [Abstract][Full Text] [Related]
9. The impact of period effects on dose level contrasts in alternating cross-over designs for first-time-in-human studies.
Koehne-Voss S; Schmidli H; Smith DM; Pigeot I
Pharm Stat; 2011; 10(1):45-9. PubMed ID: 20143341
[TBL] [Abstract][Full Text] [Related]
10. Design and analysis of crossover trials for absorbing binary endpoints.
Nason M; Follmann D
Biometrics; 2010 Sep; 66(3):958-65. PubMed ID: 19930189
[TBL] [Abstract][Full Text] [Related]
11. Sequential designs for logistic phase I clinical trials.
Liu G; Rosenberger WF; Haines LM
J Biopharm Stat; 2006; 16(5):605-21. PubMed ID: 17037261
[TBL] [Abstract][Full Text] [Related]
12. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
Gerke O; Siedentop H
Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
[TBL] [Abstract][Full Text] [Related]
13. Improved designs for dose escalation studies using pharmacokinetic measurements.
Piantadosi S; Liu G
Stat Med; 1996 Aug; 15(15):1605-18. PubMed ID: 8858785
[TBL] [Abstract][Full Text] [Related]
14. Optimal dose-finding designs with correlated continuous and discrete responses.
Fedorov V; Wu Y; Zhang R
Stat Med; 2012 Feb; 31(3):217-34. PubMed ID: 22162014
[TBL] [Abstract][Full Text] [Related]
15. Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.
Potter DM
J Biopharm Stat; 2006; 16(5):579-604. PubMed ID: 17037260
[TBL] [Abstract][Full Text] [Related]
16. Choice of designs and doses for early phase trials.
Zhou Y
Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
[TBL] [Abstract][Full Text] [Related]
17. Fractional dose-finding methods with late-onset toxicity in phase I clinical trials.
Yin G; Zheng S; Xu J
J Biopharm Stat; 2013; 23(4):856-70. PubMed ID: 23786314
[TBL] [Abstract][Full Text] [Related]
18. Designs for phase I clinical trials with multiple courses of subjects at different doses.
Fan SK; Wang YG
Biometrics; 2007 Sep; 63(3):856-64. PubMed ID: 17403103
[TBL] [Abstract][Full Text] [Related]
19. Inclusion of placebos and blinding for ascending dose first-in-human studies and other underpowered phase 1 studies has not been justified and on balance is not useful.
Parasrampuria DA; Benet LZ
Basic Clin Pharmacol Toxicol; 2015 Jul; 117(1):44-51. PubMed ID: 25406995
[TBL] [Abstract][Full Text] [Related]
20. Adaptive methods: when and how should they be used in clinical trials?
Porcher R; Lecocq B; Vray M;
Therapie; 2011; 66(4):319-26, 309-17. PubMed ID: 21851793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
